Breakthrough Therapy Designation granted to zoldonrasib for the treatment of adult patients with KRAS G12D-mutated locally ...

Merck is in talks to buy cancer drug developer Revolution Medicines in a $28 billion to $32 billion deal, the Financial Times ...

Wrexham welcome Nottingham Forest to the Stok Cae Ras stadium tomorrow evening in the third round of the FA Cup.The Red ...

RTA completes 7km Al Warqa’a 1 road upgrade, easing congestion, boosting safety, and supporting smoother travel across Dubai.

Immuneering Corporation stays a Strong Buy: pancreatic cancer combo shows 64% 12‑mo OS, strong safety, and clear catalysts ...

A sea bridge between Asia and Africa has been planned since the 1980s, but remarks from an Egyptian official in 2025 hint ...

Nordic Aqua Partners completed Stage 1 of its salmon RAS in 2024 and began harvesting salmon in April 2024. The company said ...

AbbVie stock fell after denying Revolution Medicines buyout talks. Company also cut 2025 earnings forecast to $9.90-$9.94 per ...

Zoldonrasib targets KRAS G12D-mutated non-small cell lung cancer, receiving FDA breakthrough therapy designation for its ...

Immuneering has reported updated data on atebimetinib in first-line pancreatic cancer patients, linking the MEK inhibitor to ...

Saudi Arabia's NDC suggests the baseline for the 2040 target could be recalculated and meeting it will depend on revenues ...

BANGKOK: Thailand's Food and Drug Administration (FDA) is seeking to tighten oversight of GLP-1 injection "slimming pens", ...